Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
UnitedHealth Group Incorporated's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $338.3B | |
|---|---|---|
| Revenue (ttm) | 450.1B | |
| Net income (ttm) | 15.9B | |
| EPS (ttm) | $17.5 | |
| Shares out | 897.6M | |
| P/E (trailing) | 23.3x | |
| P/E (forward) | 16.7x | |
| Dividend | $9.28 (2.28%) | |
| Volume | 2,955,783 | |
| Beta | 0.61 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $287.60B | $324.16B | $371.62B | $400.28B | $447.57B | +11.7% |
| Gross profit | $69.65B | $79.62B | $90.96B | $89.40B | $82.92B | +4.5% |
| Operating income | $23.97B | $28.44B | $32.36B | $32.29B | $18.96B | -5.7% |
| Net income | $17.29B | $20.12B | $22.38B | $14.41B | $12.06B | -8.6% |
| EPS (diluted) | $18.08 | $21.18 | $23.86 | $15.51 | $13.23 | -7.5% |
| EBITDA | $27.07B | $31.84B | $36.33B | $28.08B | $23.06B | -3.9% |
| R&D | — | — | — | — | — | — |
| SG&A | $42.58B | $47.78B | $54.63B | $53.01B | $59.59B | +8.8% |
Recent company headlines from major financial publishers.
The Base path represents the modal expectation where UnitedHealthcare maintains its market share and core profitability, while OptumHealth gradually narrows operating losses. Under this progression, operating margins trend toward normalized levels, supporting fair value expansion toward $448.25.
The Bull path requires OptumHealth care delivery margins to recover rapidly, commercial employer enrollment to gain market share, and effective contract repricing to outpace medical inflation. The reader would see confirmation through consecutive quarters of expanding operating margins in care delivery and accelerating earnings per share growth toward $578.10.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 6.0% | $553 | $592 | $643 | $717 | $833 |
| 7.0% | $473 | $494 | $521 | $556 | $603 |
| 8.0% | $420 | $433 | $448 | $468 | $492 |
| 9.0% | $381 | $389 | $399 | $411 | $426 |
| 10.0% | $351 | $357 | $364 | $372 | $381 |
Upcoming earnings date and setup when available.
De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.
| Jaar | jan | feb | mrt | apr | mei | jun | jul | aug | sep | okt | nov | dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
